OvaScience,Inc. (NASDAQ:OVAS) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

OvaScience,Inc. (NASDAQ:OVAS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition

On August3, 2017, OvaScience,Inc. (the “Company”) announced its financial results for the quarter ended June30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit99.1 to this Current Report on Form8-K.

The information in this Current Report on Form8-K (including Exhibit99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1 Press Release dated August3, 2017.


OvaScience, Inc. Exhibit
EX-99.1 2 a17-18931_1ex99d1.htm EX-99.1 Exhibit 99.1     News Release   OvaScience Reports Second Quarter 2017 Financial Results   — Fertilization of Bovine EggPC Cell-Derived Egg in OvaTure Program on Track for Year-End —   — Completed Target Enrollment in OvaPrime Clinical Safety Study; Expect to Announce Initial Safety Data in First 20 Patients by Year-End —   — Sufficiently Funded to Support Operations into 1Q 2020,…
To view the full exhibit click here

About OvaScience,Inc. (NASDAQ:OVAS)

OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.